Merck & Co., Inc. MRK
Merck & Co., Inc. (NYSE: MRK) is an oncology drug developer. Its lead program, MK-4208 (formerly TERN-701), is in Phase 2 for Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia (previously treated with at least one prior TKI and who experienced treatment failure, suboptimal response or treatment intolerance).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Keytruda (pembrolizumab) | Multiple oncology indications | antibody | Approved |
| Keytruda Qlex (pembrolizumab SC) | Multiple oncology indications | antibody | Approved |
| Gardasil/Gardasil 9 | HPV-related cancers and diseases | vaccine | Approved |
| Welireg | VHL disease, advanced RCC, pheochromocytoma and paraganglioma | small molecule | Approved |
| Capvaxive | Invasive pneumococcal disease and pneumococcal pneumonia | vaccine | Approved |
| Vaxneuvance | Invasive pneumococcal disease | vaccine | Approved |
| Prevymis | CMV infection prophylaxis | small molecule | Approved |
| Enflonsia | RSV lower respiratory tract disease prevention in infants | antibody | Approved |
| Winrevair | Pulmonary arterial hypertension | protein/peptide | Approved |
| MK-1406 (formerly CD388) | Seasonal and pandemic influenza prevention | biologic-other | Phase 3 |
| MK-4208 (formerly TERN-701) | Chronic myeloid leukemia | small molecule | Phase 2 |
| MK-2690 (SPR2015) | Cancers and tumors characterized by the KRAS G12D mutation | small molecule | Pre-clinical |
Recent results and decisions
- Oct 29, 2026positive Sac-TMT reduced risk of death by 32% and risk of disease progression or death by 41% compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer in Phase 3 TroFuse-005 trial.
Reduced Risk of Death by 32% and Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer; Results From Phase 3 TroFuse-005 Trial
Filing - Oct 29, 2026met Intismeran plus KEYTRUDA significantly reduced risk of recurrence or death by 42% compared to KEYTRUDA alone in Phase 3 INTerpath-001 trial for resected melanoma.
Intismeran Plus KEYTRUDA Significantly Reduced Risk of Recurrence or Death by 42% (HR=0.58 [95% CI, 0.45–0.75]; Two-Sided p<0.001) Compared to KEYTRUDA Alone for Patients With Completely Resected Stage IIB-IV Melanoma
Filing - Oct 29, 2026met KEYTRUDA monotherapy reduced risk of disease progression or death by 43% for certain patients with advanced or recurrent endometrial cancer with dMMR tumors in Phase 3 KEYNOTE-C93 trial.
KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With dMMR Tumors Compared to Chemotherapy; Results From Phase 3 KEYNOTE-C93 Trial
Filing
40 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.